azomycin has been researched along with rifampin in 39 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (12.82) | 29.6817 |
| 2010's | 26 (66.67) | 24.3611 |
| 2020's | 8 (20.51) | 2.80 |
| Authors | Studies |
|---|---|
| Batista-Gonzalez, A; Brunhofer, G; Fallarero, A; Gopi Mohan, C; Karlsson, D; Shinde, P; Vuorela, P | 1 |
| Chauffour, A; Jarlier, V; Ji, B; Lefrançois, S; Robert, J; Truffot, C | 1 |
| Almeida, D; Bishai, WR; Grosset, JH; Nuermberger, E; Peloquin, CA; Rosenthal, I; Tyagi, S; Williams, KN | 1 |
| Aly, S; Andries, K; Basaraba, RJ; Cantarero, L; Ehlers, S; Hoff, D; Lenaerts, AJ; Orme, IM | 1 |
| Zhang, Y | 1 |
| Grosset, J; Nuermberger, E; Tasneen, R; Tyagi, S; Williams, K | 1 |
| Cole, ST; Dhar, N; Ha, YH; Hartkoorn, RC; Sala, C; Schneider, P; Zhang, M | 1 |
| Becker, P; Dawson, R; Diacon, AH; Donald, PR; du Bois, J; Erondu, N; Ginsberg, AM; Narunsky, K; Spigelman, MK; van Niekerk, C; Venter, A | 1 |
| Amoabeng, O; Andries, K; Mdluli, KE; Minkowski, A; Nuermberger, EL; Peloquin, CA; Taylor, D; Wallis, RS; Williams, K | 1 |
| Cole, ST; Hartkoorn, RC; Lechartier, B | 1 |
| Schaberg, T | 1 |
| Allen, R; Aweeka, F; Bao, J; Cramer, Y; Dooley, KE; Haas, DW; Koletar, SL; Luetkemeyer, AF; Marzan, F; Murray, S; Park, JG; Savic, R; Sutherland, D | 1 |
| Chen, X; Gao, R; Pang, X; Zhang, Y; Zhong, D; Zhong, K | 1 |
| Dutta, NK; Karakousis, PC | 1 |
| Burger, DA; Conradie, A; Dawson, R; Diacon, AH; Donald, PR; Eisenach, K; Everitt, D; Ive, P; Mendel, CM; Ntinginya, NE; Page-Shipp, L; Pym, A; Reither, K; Schall, R; Spigelman, M; van Niekerk, C; Variava, E; Venter, A; von Groote-Bidlingmaier, F | 1 |
| Geiter, L; Mallikaarjun, S; Paccaly, A; Patil, S; Petersen, C; Shoaf, SE; Wells, C | 1 |
| Crosier, PS; Dalton, JP; Denny, WA; Hall, CJ; Okuda, KS; Swift, S; Uy, B; Wiles, S | 1 |
| Fattorini, L; Giannoni, F; Iacobino, A; Mustazzolu, A; Piccaro, G | 1 |
| Berisio, R; Romano, M; Ruggiero, A; Squeglia, F | 1 |
| Mendel, C; Murray, S; Spigelman, M | 1 |
| Cox, V; Furin, J; Lessem, E | 1 |
| Aguilar-Ayala, DA; Cnockaert, M; Gonzalez-Y-Merchand, J; Martin, A; Palomino, JC; Vandamme, P | 1 |
| Falzon, D; Halleux, CM; Jaramillo, E; Merle, C; Mirzayev, F; Olliaro, P; Weyer, K | 1 |
| Ade, S; Alikhanova, N; Benedetti, G; Cox, H; Daniels, J; De Azevedo, V; Edwards, J; Ferlazzo, G; Furin, J; Hughes, J; Isaakidis, P; Kock, Y; Mohr, E; Reuter, A; Shroufi, A; Steele, SJ; Trivino Duran, L | 1 |
| Flexner, C; Moss, DM; Owen, A; Podany, AT; Rajoli, RKR; Siccardi, M; Swindells, S | 1 |
| Balanag, V; Bielskiene, V; Cadena, E; Caoili, J; Cirule, A; Danilovits, M; Davidaviciene, E; Domente, L; Geiter, LJ; Gupta, R; Hafkin, J; Hittel, N; Lizarbe, V; Patientia, R; Petersen, C; Sanchez, E; Segura, P; Staples, S; Ticona, E; Variava, E; von Groote-Bidlingmaier, F; Wells, C; Yu, C | 1 |
| Nair, SG; Patel, DB; Patel, HD; Rathwa, SK; Vasava, MS | 1 |
| Fattorini, L; Giannoni, F; Iacobino, A; Pardini, M; Piccaro, G | 1 |
| Everitt, D; Nedelman, JR; Salinger, DH; Subramoney, V | 1 |
| Cook-Scalise, S; Denkinger, CM; Dowdy, DW; Kendall, EA; Malhotra, S | 1 |
| Burger, DA; Conradie, A; Conradie, F; Crook, AM; Dawson, R; Diacon, AH; Everitt, DE; Haraka, F; Li, M; Mendel, CM; Ntinginya, NE; Okwera, A; Rassool, MS; Reither, K; Sebe, MA; Spigelman, M; Staples, S; Tweed, CD; van Niekerk, CH; Variava, E | 1 |
| Beko, B; Cox, H; Daniels, J; De Avezedo, V; Ferlazzo, G; Furin, J; Hughes, J; Isaakidis, P; Kock, Y; Makhanda, G; Mohr-Holland, E; Reuter, A; Trivino Duran, L | 1 |
| Comins, K; Conradie, F; Cramer, YS; De Los Rios, J; Diacon, AH; Donahue, K; Dooley, KE; Hafner, R; Lama, JR; Maartens, G; Moran, L; Morganroth, J; Rosenkranz, SL; Shenje, J; von Groote-Bidlingmaier, F | 1 |
| de Jong, BC; Decroo, T; Gils, T; Lynen, L; Van Deun, A | 1 |
| Kumari, D; Perveen, S; Sharma, R; Singh, K | 1 |
| Ahmed, S; Bastard, M; Franke, MF; Grium Tefera, D; Hewison, C; Holtzman, D; Huerga, H; Islam, S; Jacques Leblanc, G; Khan, PY; Khan, U; Kumsa, A; Lachenal, N; Leonovich, O; Mamsa, S; Manzur-Ul-Alam, M; Melikyan, N; Mitnick, CD; Myint, Z; Osso, E; Padayachee, S; Rafi Siddiqui, M; Rashitov, M; Rich, ML; Salahuddin, N; Salia, G; Sánchez, E; Serobyan, A; Seung, KJ; Varaine, F; Vetushko, D; Yeghiazaryan, L | 1 |
| Bagdasaryan, TR; Bateson, A; Borisov, S; Conradie, F; Crook, AM; Egizi, E; Everitt, D; Fabiane, SM; Foraida, S; Holsta, A; Howell, P; Hunt, R; Li, M; McHugh, TD; Mendel, CM; Mikiashvili, L; Ngubane, N; Olugbosi, M; Samoilova, A; Skornykova, S; Spigelman, M; Sun, E; Timm, J; Tudor, E; Tweed, CD; Variava, E; Wills, GH; Yablonskiy, P | 1 |
| Apolisi, I; Beko, B; Cengani, L; Cox, H; Daniels, J; Fatshe, S; Furin, J; Gumede, N; Joseph, K; Mathee, S; Maugans, C; Memani, B; Reuter, A; Tyeku, N | 1 |
| Barnes, G; Dawson, R; Dooley, KE; Dorman, SE; Friedman, A; Gupte, N; Hendricks, B; Ignatius, EH; Narunsky, K; Smit, T; Whitelaw, C | 1 |
6 review(s) available for azomycin and rifampin
| Article | Year |
|---|---|
Advances in the treatment of tuberculosis.
Topics: Adamantane; AIDS-Related Opportunistic Infections; Animals; Anti-Bacterial Agents; Antitubercular Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Drug Therapy, Combination; Drugs, Investigational; Ethylenediamines; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin; Treatment Refusal; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2007 |
[Tuberculosis: new treatment options and updated recommendations].
Topics: Antitubercular Agents; Aza Compounds; Cross-Sectional Studies; Diagnosis, Differential; Diarylquinolines; Fluoroquinolones; Germany; Humans; Moxifloxacin; Nitroimidazoles; Oxazoles; Prognosis; Quinolines; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2013 |
Molecular Players in Tuberculosis Drug Development: Another Break in the Cell Wall.
Topics: Antitubercular Agents; Benzothiazoles; Cell Wall; Drug Discovery; Humans; Molecular Docking Simulation; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin; Tuberculosis | 2017 |
Development of new drug-regimens against multidrug-resistant tuberculosis.
Topics: Adamantane; Antitubercular Agents; Diarylquinolines; Drug Development; Drug Therapy, Combination; Duration of Therapy; Ethambutol; Ethylenediamines; Humans; Isoniazid; Macrolides; Medication Adherence; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis, Multidrug-Resistant | 2019 |
Pretomanid for tuberculosis: a systematic review.
Topics: Antitubercular Agents; Humans; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
Topics: Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Ethambutol; Extensively Drug-Resistant Tuberculosis; Humans; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2022 |
9 trial(s) available for azomycin and rifampin
| Article | Year |
|---|---|
Phase II dose-ranging trial of the early bactericidal activity of PA-824.
Topics: Adolescent; Adult; Antitubercular Agents; Drug Administration Schedule; Ethambutol; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary; Young Adult | 2012 |
Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.
Topics: Adult; Alkynes; Antitubercular Agents; Antiviral Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Humans; Lopinavir; Male; Middle Aged; Nitroimidazoles; Pharmacogenetics; Rifampin; Ritonavir; Young Adult | 2014 |
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pul
Topics: Adolescent; Adult; Antitubercular Agents; Colony Count, Microbial; Drug Therapy, Combination; Ethambutol; Female; Fluoroquinolones; Humans; Isoniazid; Male; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary; Young Adult | 2015 |
Delamanid Coadministered with Antiretroviral Drugs or Antituberculosis Drugs Shows No Clinically Relevant Drug-Drug Interactions in Healthy Subjects.
Topics: Adult; Alkynes; Anti-HIV Agents; Antitubercular Agents; Benzoxazines; Cyclopropanes; Drug Combinations; Drug Interactions; Ethambutol; Female; Healthy Volunteers; Humans; Isoniazid; Male; Nitroimidazoles; Oxazoles; Pyrazinamide; Rifampin | 2016 |
Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial.
Topics: Antitubercular Agents; Double-Blind Method; Drug Administration Schedule; Drug Monitoring; Drug Therapy, Combination; Female; Humans; Isoniazid; Male; Middle Aged; Nitroimidazoles; Oxazoles; Rifampin; Sputum; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Bedaquiline, moxifloxacin, pretomanid, and pyrazinamide during the first 8 weeks of treatment of patients with drug-susceptible or drug-resistant pulmonary tuberculosis: a multicentre, open-label, partially randomised, phase 2b trial.
Topics: Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Therapy, Combination; Humans; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Rifampin; South Africa; Sputum; Tanzania; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Uganda | 2019 |
QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Drug Therapy, Combination; Electrocardiography; Female; Humans; Male; Nitroimidazoles; Oxazoles; Peru; Rifampin; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant | 2021 |
Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Topics: Aminoglycosides; Antitubercular Agents; Diarylquinolines; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Rifampin; Risk Assessment; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2022 |
Assessing Pretomanid for Tuberculosis (APT), a Randomized Phase 2 Trial of Pretomanid-Containing Regimens for Drug-Sensitive Tuberculosis: 12-Week Results.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Isoniazid; Mice; Nitroimidazoles; Pyrazinamide; Rifampin; Tuberculosis, Pulmonary | 2023 |
24 other study(ies) available for azomycin and rifampin
| Article | Year |
|---|---|
Exploration of natural compounds as sources of new bifunctional scaffolds targeting cholinesterases and beta amyloid aggregation: the case of chelerythrine.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenanthridines; Binding Sites; Butyrylcholinesterase; Catalytic Domain; Cholinesterase Inhibitors; Humans; Isoquinolines; Kinetics; Molecular Docking Simulation; Structure-Activity Relationship | 2012 |
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.
Topics: Acetamides; Amikacin; Animals; Anti-Bacterial Agents; Anti-Infective Agents; Aza Compounds; Colony Count, Microbial; Diarylquinolines; Dose-Response Relationship, Drug; Female; Fluoroquinolones; Foot; In Vitro Techniques; Linezolid; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium ulcerans; Nitroimidazoles; Oxazolidinones; Quinolines; Rifampin; Streptomycin; Survival Analysis; Time Factors | 2006 |
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Disease Models, Animal; Drug Therapy, Combination; Ethambutol; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Rifampin; Secondary Prevention; Time Factors; Tuberculosis, Pulmonary | 2006 |
Location of persisting mycobacteria in a Guinea pig model of tuberculosis revealed by r207910.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Diarylquinolines; Female; Granuloma; Guinea Pigs; Hypoxia; Isoniazid; Lung; Mycobacterium tuberculosis; Nitroimidazoles; Pyrazinamide; Quinolines; Radiation-Sensitizing Agents; Rifampin; Spleen; Tuberculosis | 2007 |
Enhanced bactericidal activity of rifampin and/or pyrazinamide when combined with PA-824 in a murine model of tuberculosis.
Topics: Animals; Antibiotics, Antitubercular; Antitubercular Agents; Colony Count, Microbial; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Isoniazid; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Nitroimidazoles; Pyrazinamide; Recurrence; Rifampin; Tuberculosis, Pulmonary | 2008 |
Simple model for testing drugs against nonreplicating Mycobacterium tuberculosis.
Topics: Antitubercular Agents; Aza Compounds; Fluoroquinolones; Isoniazid; Meropenem; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Streptomycin; Thienamycins | 2010 |
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis.
Topics: Animals; Antitubercular Agents; Drug Therapy, Combination; Female; Isoniazid; Mice; Mice, Inbred BALB C; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2012 |
In vitro combination studies of benzothiazinone lead compound BTZ043 against Mycobacterium tuberculosis.
Topics: Adamantane; Antitubercular Agents; Aza Compounds; Diarylquinolines; Drug Combinations; Drug Synergism; Ethambutol; Ethylenediamines; Fluoroquinolones; Isoniazid; Meropenem; Microbial Sensitivity Tests; Microbial Viability; Moxifloxacin; Mycobacterium tuberculosis; Nitroimidazoles; Quinolines; Rifampin; Spiro Compounds; Thiazines; Thienamycins | 2012 |
Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects.
Topics: Animals; Antifungal Agents; Candida glabrata; Candidiasis; Cell Line; Female; Fluconazole; Fungal Proteins; Humans; Immunoblotting; Ketoconazole; Lectins; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Nitroimidazoles; Open Reading Frames; Rifampin | 2014 |
PA-824 is as effective as isoniazid against latent tuberculosis infection in C3HeB/FeJ mice.
Topics: Animals; Antitubercular Agents; Disease Models, Animal; Female; Isoniazid; Latent Tuberculosis; Lung; Mice; Mice, Inbred C3H; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin | 2014 |
Screening of anti-mycobacterial compounds in a naturally infected zebrafish larvae model.
Topics: Animals; Antitubercular Agents; Drug Evaluation, Preclinical; Larva; Luminescent Measurements; Mycobacterium marinum; Nitroimidazoles; Rifampin; Staining and Labeling; Zebrafish | 2017 |
Mycobacterium tuberculosis Is Selectively Killed by Rifampin and Rifapentine in Hypoxia at Neutral pH.
Topics: Anaerobiosis; Antitubercular Agents; Hydrogen-Ion Concentration; Isonicotinic Acids; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Phenazines; Quinolines; Rifampin; Thiazoles | 2017 |
TB Alliance regimen development for multidrug-resistant tuberculosis.
Topics: Antitubercular Agents; Clinical Protocols; Diarylquinolines; Dose-Response Relationship, Drug; Ethambutol; Extensively Drug-Resistant Tuberculosis; Fluoroquinolones; Humans; Isoniazid; Linezolid; Moxifloxacin; Nitroimidazoles; Pyrazinamide; Randomized Controlled Trials as Topic; Research Design; Rifampin; Tuberculosis, Multidrug-Resistant | 2016 |
Bedaquiline or delamanid for rifampin-resistant tuberculosis?
Topics: Antitubercular Agents; Diarylquinolines; Drug Resistance, Bacterial; Humans; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Rifampin; Tuberculosis, Multidrug-Resistant | 2017 |
Antimicrobial activity against Mycobacterium tuberculosis under in vitro lipid-rich dormancy conditions.
Topics: Amikacin; Anti-Bacterial Agents; Antitubercular Agents; Drug Tolerance; Fluoroquinolones; Genetic Fitness; Genotype; Humans; Lipid Metabolism; Lipids; Microbial Sensitivity Tests; Models, Biological; Moxifloxacin; Mycobacterium Infections, Nontuberculous; Mycobacterium tuberculosis; Nitroimidazoles; Rifampin | 2018 |
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis.
Topics: Antitubercular Agents; Communicable Disease Control; Databases, Factual; Diarylquinolines; Humans; Infectious Disease Medicine; Isoniazid; Mycobacterium tuberculosis; Nitroimidazoles; Oxazoles; Patient Safety; Public Health; Rifampin; Tuberculosis, Multidrug-Resistant; World Health Organization | 2018 |
Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa.
Topics: Adult; Antitubercular Agents; Female; Humans; Logistic Models; Male; Nitroimidazoles; Oxazoles; Retrospective Studies; Rifampin; South Africa; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2018 |
Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study.
Topics: Adolescent; Adult; Antitubercular Agents; Diarylquinolines; Drug Administration Schedule; Drug Liberation; Drug Therapy, Combination; Female; Humans; Injections, Intramuscular; Isoniazid; Latent Tuberculosis; Male; Middle Aged; Nitroimidazoles; Oxazoles; Proof of Concept Study; Rifampin; Treatment Outcome; Young Adult | 2018 |
The Combination Rifampin-Nitazoxanide, but Not Rifampin-Isoniazid-Pyrazinamide-Ethambutol, Kills Dormant Mycobacterium tuberculosis in Hypoxia at Neutral pH.
Topics: Antitubercular Agents; Drug Combinations; Drug Therapy, Combination; Ethambutol; Humans; Hydrogen-Ion Concentration; Hypoxia; Isoniazid; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Nitroimidazoles; Oxazolidinones; Pyrazinamide; Rifampin; Tuberculosis | 2019 |
Population Pharmacokinetics of the Antituberculosis Agent Pretomanid.
Topics: Antitubercular Agents; Biological Availability; Clinical Trials as Topic; Extensively Drug-Resistant Tuberculosis; Female; HIV Infections; Humans; Lopinavir; Male; Nitroimidazoles; Rifampin; Ritonavir; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2019 |
Estimating the impact of a novel drug regimen for treatment of tuberculosis: a modeling analysis of projected patient outcomes and epidemiological considerations.
Topics: Adult; Antitubercular Agents; Diarylquinolines; Humans; Markov Chains; Nitroimidazoles; Prevalence; Pyrazinamide; Rifampin; South Africa; Treatment Outcome; Tuberculosis; Tuberculosis, Multidrug-Resistant | 2019 |
Correspondence regarding "Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa".
Topics: Humans; Nitroimidazoles; Oxazoles; Retrospective Studies; Rifampin; South Africa; Tuberculosis, Multidrug-Resistant | 2020 |
Safety and Effectiveness Outcomes From a 14-Country Cohort of Patients With Multi-Drug Resistant Tuberculosis Treated Concomitantly With Bedaquiline, Delamanid, and Other Second-Line Drugs.
Topics: Antitubercular Agents; Clofazimine; Cohort Studies; Diarylquinolines; Electrolytes; Fluoroquinolones; Humans; Linezolid; Nitroimidazoles; Oxazoles; Prospective Studies; Rifampin; Tuberculosis, Multidrug-Resistant | 2022 |
Pediatric delamanid treatment for children with rifampicin-resistant TB.
Topics: Antitubercular Agents; Child; Humans; Nitroimidazoles; Oxazoles; Rifampin; Tuberculosis, Multidrug-Resistant | 2022 |